Compositions comprising decitabine and tetrahydrouridine and uses thereof
AssigneeThe Board of Trustees of the University of Illinois
InventorsJoseph Desimone, Yogen Saunthararajah
Life of this patent
Estimating the term…
Abstract
Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.
Claims16
-20. (canceled)
A composition for oral administration comprising about 10 to about 150 mg/m decitabine and about 100 to about 500 mg/m tetrahydrouridine and a pharmaceutically acceptable excipient, wherein the tetrahydrouridine is located on a surface of capsule or the tablet and the decitabine is located within the capsule or the tablet.
A method for treating a hematological or solid malignancy in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of decitabine and tetrahydrouridine, wherein the tetrahydrouridine is bio-available about 15 to about 180 minutes before the decitabine.
Dependencies are inferred from the claim text.